Lates News

Budget weight-loss drug supplier Hims & Hers Health reported second-quarter revenue of $544.8 million, slightly below analysts' expectations of $552.1 million. Operating expenses for the second quarter were $389.5 million, a 59% decrease compared to the previous year. The company expects full-year revenue to be between $2.3 billion to $2.4 billion, slightly below analysts' expectations of $2.36 billion. Adjusted EBITDA for the full year is estimated to be between $295 million to $335 million, slightly below analysts' expectations of $322.1 million. The company expects third-quarter revenue to be between $570 million to $590 million, slightly below analysts' expectations of $584.2 million.